N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
N/A N=107 Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Influenza
Primary: Determination of Immune Response to Vaccination. — 45 participants
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 4 N=166 Immunologic Response to Influenza Vaccination in Children and Adolescents
Influenza, Human · Immune Response
Primary: Determining Seroconversion Response - Change in HI Titers From Pre- to Post Vaccination — 20; 14; 9; 11 Participants — p=0.28
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Phase 2 N=729 Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
Influenza · Orthomyxoviruses · Myxovirus Infection
Primary: Summary of the Pre- and Post-Vaccination Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigens. — 25.9; 26.4; 26.6; 184.8 Titers
Phase 2 N=98 Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Healthy Volunteer
Primary: Microneutralization Titers — 0.769; 1.313; 1.716; 1.333 Log2 Fold Change
N/A N=48 Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Influenza · Vaccine Virus Shedding
Primary: Number of Participants Shedding Each Vaccine Virus Measured by qPCR of Nasosorption Samples — 31 participants
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 4 N=136 Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
Influenza
Primary: Number of Participants Who Received the Influenza Vaccine — 59; 37; 40 Participants
Phase 4 N=13 The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants
Phase 3 N=3,837 Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines. — 28.25…
Phase 4 N=413 Comparison of Three Licensed Influenza Vaccines
Influenza
Primary: Mean Change of HAI Serum Antibody Titers to A/California/07/09 (H1N1) — 1937; 383; 607 titer
N/A N=66 Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants
Phase 4 N=51 Revealing Protective Immunity to Influenza Using Systems Immunology
Influenza
Primary: Quantification of Antibody Titers — 37.4; 24.6; 6.81 Antibody titer
Phase 4 N=131 Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Immune Response to Influenza Vaccine · Influenza A Virus Infection · Influenza B Virus Infection
Primary: Hemagglutination Inhibition (HI) Titer Response to Vaccine and Circulating Strains of Influenza — 99; 295; 96; 100 Titers
Phase 4 N=120 Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Fluzone® Vaccination — 40; 10; 4; 6 Participants
Phase 4 N=121 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Influenza
Primary: Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone® — 15; 7; 0; 2 Percentage of Participants
Phase 4 N=20 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 20 Participants
Phase 2 N=601 Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43. — 4.64; 4.10; 4.61; 14 Area…
Phase 4 N=241 Gene Signatures of Influenza Vaccine Responses in Older Adults
Influenza
Primary: Innate Cell IFNa2a Production — 112.3650; 131.4214; 107.5846; 134.9071 pg/mL
Phase 4 N=22 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 5; 5; 6; 3 Participants
Phase 4 N=51 B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 6; 24; 21 Participants
Phase 4 N=73 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine — 6; 6; 8; 6 Participants